NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
NOVAVAX INC (NVAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 124.70% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2021-05-10
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2021-03-31 was 124.70%, a 6.66% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2020-03-31 was 133.60%, a 19.61% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2019-03-31 was 111.70%, a 2.00% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2018-09-30 was 113.64%, a 1.96% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2018 was 93.31%, a 4.95% increase from fiscal 2017.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2017 was 88.91%, a 53.66% increase from fiscal 2016.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2016 was 57.86%, a 7.99% increase from fiscal 2015.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2015 was 53.58%, a 2.12% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | 124.70% 10-Q · filed 2021-05-10 | ||||
| 2020-03-31 | 133.60% 10-Q · filed 2021-05-10 | ||||
| 2019-03-31 | 111.70% 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | 93.31% 10-K · filed 2019-03-18 | ||||
| 2018-09-30 | 113.64% 10-Q · filed 2018-11-07 | 113.64% 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | 113.68% 10-Q · filed 2018-08-08 | 113.68% 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | 113.98% 10-Q · filed 2018-05-09 | ||||
| 2017-12-31 | 88.91% 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | 111.46% 10-Q · filed 2018-11-07 | 88.91% 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | 106.92% 10-Q · filed 2018-08-08 | 88.91% 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | 88.91% 10-Q · filed 2018-05-09 | ||||
| 2016-12-31 | 57.86% 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | 58.58% 10-Q · filed 2017-11-07 | 57.86% 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | 58.10% 10-Q · filed 2017-08-08 | 57.86% 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | 57.86% 10-Q · filed 2017-05-08 | ||||
| 2015-12-31 | 53.58% 10-K · filed 2018-03-14 | ||||
| 2015-09-30 | 54.93% 10-Q · filed 2016-11-09 | 53.58% 10-Q · filed 2016-11-09 | |||
| 2015-06-30 | 54.18% 10-Q · filed 2016-08-09 | 53.58% 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | 53.58% 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | 52.47% 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | 52.75% 10-Q · filed 2015-11-09 | 52.40% 10-Q · filed 2015-11-09 | 52.47% 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | 52.87% 10-Q · filed 2015-08-10 | 52.47% 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | 52.47% 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | 51.55% 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | 56.75% 10-Q · filed 2014-11-06 | 55.81% 10-Q · filed 2014-11-06 | |||
| 2013-06-30 | 55.81% 10-Q · filed 2014-08-07 | 55.81% 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | 69.23% 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | 75.50% 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | 76.60% 10-Q · filed 2013-11-12 | 75.47% 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | 75.47% 10-Q · filed 2013-08-08 | 75.47% 10-Q · filed 2013-08-08 | |||
| 2012-03-31 | 75.52% 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | 73.30% 10-K · filed 2014-03-12 | ||||
| 2011-09-30 | 75.86% 10-Q · filed 2012-11-09 | 73.28% 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | 73.28% 10-Q · filed 2012-08-09 | 73.28% 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | 97.00% 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |